Vera Therapeutics to Participate at Upcoming Investor Conferences
VERABRISBANE, Calif., Aug. 26, 2025 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a late clinical-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases, today announced that the Company’s management team will present and participate in one-on-one meetings at upcoming investor conferences.
Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
VERABRISBANE, Calif., Aug. 08, 2025 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA) today announced that, on August 4, 2025, the Compensation Committee of Vera’s Board of Directors granted inducement awards consisting of non-qualified stock options to purchase 99,000 shares of Class A common stock and restricted stock units (RSUs) underlying 48,200 shares of Class A common stock to eight (8) new employees under the Vera Therapeutics, Inc. 2024 Inducement Plan (Inducement Plan). The Compensation Committee approved the awards as an inducement material to the new employees’ employment in accordance with Nasdaq Listing Rule 5635(c)(4).
Vera Therapeutics Secures $500M Credit Facility with Lower Rates, Boosting Financial Flexibility
VERAScotiabank Maintains Sector Outperform on Vera Therapeutics, Raises Price Target to $65
VERAKidney Health-Focused Vera Therapeutics Stock Price Spikes On Heels Of Successful Trial Data
VERAVera Therapeutics' share price surged over 65% during the pre-market trading session after the company released ORIGIN Phase 3 trial data.
HC Wainwright & Co. Maintains Buy on Vera Therapeutics, Raises Price Target to $85
VERAVera Therapeutics Says Atacicept ORIGIN Phase 3 Trial Meets Primary Endpoint Of Reduction In UPCR For IgAN Treatment; Vera Currently Plans To Submit BLA For Accelerated Approval To FDA In 4Q 2025
VERAWedbush Maintains Neutral on Vera Therapeutics, Lowers Price Target to $26
VERACantor Fitzgerald Maintains Overweight on Vera Therapeutics, Lowers Price Target to $100
VERAVera Therapeutics Q1 EPS $(0.81) Misses $(0.73) Estimate
VERAHC Wainwright & Co. Assumes Vera Therapeutics at Buy, Announces Price Target of $75
VERAKidney Disease-Focused Vera Therapeutics Concludes Enrollment In Pivotal Study, Targets 2026 Commercial Launch
VERAVera Therapeutics completes enrollment in Phase 3 atacicept trial for IgAN, with interim efficacy results expected this quarter to support 2025 FDA filing.
Vera Therapeutics Announces Full Enrollment In ORIGIN Phase 3 Trial For Atacicept In IgAN
VERAJP Morgan Maintains Overweight on Vera Therapeutics, Lowers Price Target to $71
VERAGuggenheim Maintains Buy on Vera Therapeutics, Raises Price Target to $61
VERAVera Therapeutics FY 2024 GAAP EPS $(2.75) Beats $(2.83) Estimate
VERAWhat's Going On With Vera Therapeutics Stock?
VERAVera Therapeutics shares are trading lower by 4.7% Monday afternoon. The company announced an exclusive license agreement with Stanford University for VT-109.
Vera Therapeutics Announced An Exclusive License Agreement With Stanford University For Fusion Protein Targeting BAFF And APRIL, Known As VT-109, With Therapeutic Potential Across The Spectrum Of B Cell-mediated Diseases For Undisclosed Upfront And Milest
VERAJP Morgan Maintains Overweight on Vera Therapeutics, Raises Price Target to $75
VERAHC Wainwright & Co. Initiates Coverage On Vera Therapeutics with Buy Rating, Announces Price Target of $35
VERA